Calcium channel blocker use and serum ferritin in adults with hypertension

Iron overload cardiomyopathy is becoming more prevalent, and early recognition and intervention may alter outcomes. Calcium channels are key transporters of iron under iron-overloaded conditions, and potentially represent a new therapeutic target for iron overload. The purpose of this study was to e...

Full description

Saved in:
Bibliographic Details
Published in:Biometals 2012-06, Vol.25 (3), p.563-568
Main Authors: Mainous III, Arch G., Weinberg, Eugene D., Diaz, Vanessa A., Johnson, Sharleen P., Hulihan, Mary M., Grant, Althea M.
Format: Article
Language:English
Subjects:
Adult
Adults
Aged
Biochemistry
Biomedical and Life Sciences
Calcium
Calcium Channel Blockers - therapeutic use
Calcium channels
Cell Biology
Channels
Chelating agents
Data Collection
Female
Ferritin
Ferritins - blood
Humans
Hypertension
Hypertension - blood
Hypertension - drug therapy
Iron
Iron Overload - blood
Iron Overload - drug therapy
Life Sciences
Male
Medicine/Public Health
Microbiology
Middle Aged
Pharmacology/Toxicology
Plant Physiology
Serums
Vitamin C
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iron overload cardiomyopathy is becoming more prevalent, and early recognition and intervention may alter outcomes. Calcium channels are key transporters of iron under iron-overloaded conditions, and potentially represent a new therapeutic target for iron overload. The purpose of this study was to examine the relationship between Calcium channel blocker (CCB) use and serum ferritin among adults with diagnosed hypertension. We analyzed the nationally representative NHANES (National Health and Nutrition Examination Survey) 1999–2002 for adults ≥40 years with diagnosed hypertension. The association between CCBs and serum ferritin was assessed using a t-test and adjusted multiple regressions.The study population included 2143 individuals (representing 37.4 million individuals, 42.0 % males). 12.6 % of the population reported taking CCBs in the last month. Individuals taking CCBs had lower mean serum ferritin (129.3 ng/mL versus 154.5 ng/mL, p = 0.02). After adjusting for age, sex, menopause and hysterectomy status for women, race/ethnicity, and C-reactive protein, mean serum ferritin for individuals taking CCBs was 26.3 ng/mL lower than for those not taking CCBs (p = 0.01). In an adjusted regression, individuals who took CCBs and had a daily vitamin C intake of ≥500 mg had a mean serum ferritin that was 60.1 ng/mL lower than people not taking CCBs and with daily vitamin C 
ISSN:0966-0844
1572-8773
DOI:10.1007/s10534-012-9536-8